Incompatibility of synthetic tetraicosapeptide corticotrophin with the present USP and International Corticotrophin Standard.

Abstract

COBTICOTROPHIN, unlike insulin or the octapeptides of the posterior lobe of the pituitary gland, is known to exist in different biological forms, due to inconsistencies in bioassays in which various routes of administration are used. The first hormone preparations used were of the same type as the first and second International Standard, that is, crude Corticotrophin—a glacial acetic acid extract of pituitary glands. When in 1951 the oxycellulose adsorption method of Astwood et al.1 yielded a highly purified hormone, the bioassays carried out by subcutaneous injections into hypophysectomized rats showed, on the average, potency estimates three times greater than the classical assay method (Sayers test) which involves intravenous injection. This phenomenon led to a type distinction of oxycel-purified ACTH from crude Corticotrophin, the former being called Corticotrophin A (Wolfson2). Another attempt to purify Corticotrophin involving peptic or strongly acid hydrolysis yielded preparations of lower molecular size (about 28 amino-acid residues), which also differed biologically from crude Corticotrophin3. In this case the ratio of potencies observed after subcutaneous and intravenous comparison with the latter was reversed and of the order of 1 : 4. This third biological ACTH type was designated Corticotrophin B or actide (ref. 2). The foregoing ratios were obtained in rats but appear, in the main, to agree with those in man so far as crude Corticotrophin and Corticotrophin A are concerned. Bearing in mind that ACTH is mainly given subcutaneously (extravascularly), Corticotrophin A may be regarded as the most important type of native ACTH due to its high degree of purity and favourable efficiency when given extravascularly. It is partly for these reasons that the now official International and U.S.P. Corticotrophin Standard preparations are of the corticotrophin A type, a fact which has practically eliminated bioassay discrepancies (crude corticotrophin is now rarely used). The reasons for the foregoing bioassay discrepancies are unknown, but it is most likely that they lie in the different rates of inactivation of the different types of ACTH at the site of extravascular administration.